Open an account

Emergent BioSolutions

EBS · NYSE

$6.29−$0.07 (−1.10%)TodayMarket closed ·
Prev close $6.36

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 900 full-time employees. The company went IPO on 2006-11-15. The company is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Employees
900
Headquarters
Gaithersburg, Maryland
Listed
Nov 15, 2006
Sector
Health Care
Industry
Biotechnology
Website
emergentbiosolutions.com

EBS key statistics

Market cap
322.51M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.08M
Volume
1.31M
Open price
$6.34
High today
$6.34
Low today
$6.04
52 Week high
$14.06
52 Week low
$4.36

Emergent BioSolutions (EBS) at a glance

As of Oct 20, 2026, Emergent BioSolutions (EBS) shares are priced at $6.29, giving the company a market cap of 322.51M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.04 and $6.34. The current price is 4.1% above the day's low and 0.8% below its high.

Volume so far is 1.31M shares, above the average of 1.08M shares a day.

Over the past year Emergent BioSolutions has ranged from $4.36 to $14.06, and now sits 20% of the way up that range.

Emergent BioSolutions met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.60 per share against an estimate of $0.1111.

The average analyst price target is $11.22, 78.4% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold0.0%
  • Sell50.0%
Price target · 3 analystsAvg $11.22
Low
$10.10
Now
$6.29
High
$12.60

EBS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 395.5% on average.

  1. Q3 FY24: reported $1.37 per share against an estimate of $0.1414
  2. Q4 FY24: reported $0.05 per share against an estimate of -$0.50
  3. Q1 FY25: reported $0.71 per share against an estimate of $0.4444
  4. Q2 FY25: reported $0.16 per share against an estimate of -$0.4949
  5. Q3 FY25: reported $1.06 per share against an estimate of -$0.1212
  6. Q4 FY25: reported -$0.43 per share against an estimate of $0.1111
  7. Q1 FY26: reported $0.21 per share against an estimate of -$0.2525
  8. Q2 FY26: reported $0.60 per share against an estimate of $0.1111

EBS news

  • Press releaseBusiness Wire

    Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl

  • Press releaseBusiness Wire

    Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026

  • 'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg

  • Erica Kollmann

    Novavax Shorts on Edge as Russia Plague Fears Spread

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

  • Press releaseGlobe Newswire

    Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Similar companies

Companies in the same industry as Emergent BioSolutions

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.